Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 5/20 | 0.51 |
| ▸ | FEN1 | P39748 | 5/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | FLT1 | P17948 | 9/20 | 0.45 |
| ▸ | TEK | Q02763 | 6/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | PLK4 | O00444 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452527 | 0.82 | CYP3A4 (0.50) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL22677307 | 0.82 | CYP3A4 (0.50) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL26106772 | 0.80 | CYP3A4 (0.56) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL29407664 | 0.80 | CYP3A4 (0.56) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL24772741 | 0.77 | CYP2C9 (0.51) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL30680183 | 0.77 | CYP2C9 (0.51) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL31128894 | 0.76 | EPHB4 (0.56) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL22659133 | 0.76 | CYP3A4 (0.44) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL29452546 | 0.76 | CYP3A4 (0.44) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 | |
| SCHEMBL24772742 | 0.76 | CYP3A4 (0.49) | ALOX5APFEN1FGFR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| EP-3968999-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | ALOX5AP 3502/4885FEN1 1277/4885FGFR1 3/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | ALOX5AP 3502/4885FEN1 1277/4885FGFR1 3/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | ALOX5AP 3502/4885FEN1 1277/4885FGFR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.